How would you manage liver-metastatic pancreatic neuroendocrine tumor after progression on a somatostatin analogue, chemotherapy, immune checkpoint blockade, and embolization?

The optimal sequencing of systemic therapy beyond somatostatin analogs (SSAs) in patients with pancreatic NETs (pNETs) remains to be determined. Assuming that regional therapy is not feasible, there are several options such as capecitabine/temozolomide (CAPTEM), everolimus, sunitinib, and PRRT. The ...